中国男性Alport综合征患者COL4A5基因突变基因型-表型相关性及对肾素-血管紧张素-醛固酮系统阻滞剂反应的分析
该回顾性队列研究纳入187例经病理和基因分析确诊的中国男性X连锁Alport综合征患者,评估不同COL4A5基因突变类型与临床表型及RAAS阻滞剂疗效的关系。结果显示截短突变患者ESRD中位年龄22岁,非截短突变39岁;RAAS阻滞剂分别延迟ESRD 16年和3年,且疗效呈时间依赖性。
要点
- 截短突变者ESRD中位年龄22岁,非截短突变者39岁。
- RAAS阻滞剂使非截短突变者ESRD延迟16年,截短突变者延迟3年。
- 治疗每延长6个月,ESRD进展风险降低7%(HR 0.93)。
核心结论
- 男性XLAS患者的临床特征和对RAAS阻滞剂的反应与COL4A5基因突变基因型强相关。
- COL4A5基因突变分型是评估Alport综合征预后的必要且有用的工具。
研究设计与样本
- 回顾性队列研究,纳入187例经病理检查和基因分析确诊的中国男性XLAS患者。
- 采用Kaplan-Meier法和Cox比例风险模型评估不同基因型及治疗条件下进展至ESRD的年龄和风险。
主要发现
- 转录本类型与肾脏结局强相关,截短突变者ESRD中位发病年龄22岁,非截短突变者39岁。
- RAAS阻滞剂使非截短突变者ESRD发病延迟16年,使截短突变者延迟3年。
- RAAS阻滞剂疗效呈时间依赖性,治疗时长每增加6个月,进展至ESRD的风险降低7%[HR 0.93(95%CI 0.89-0.96);P < 0.001]。
临床怎么用
- 作者认为,COL4A5基因突变分型是评估Alport综合征患者预后的必要且有用的工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alport syndrome (AS) is an inherited type IV collagen-related disorder with an irreversible tendency to progress to end-stage renal disease (ESRD). X-linked AS (XLAS) is caused by mutations in the COL4A5 gene. The aim of this study was to investigate the effects of underlying mutations on clinical manifestations and the response to therapy in XLAS. METHODS: We conducted a retrospective cohort study of 187 Chinese male patients with XLAS confirmed by pathological examination and genetic analysis. The Kaplan-Meier method and Cox proportional hazards model were used to assess the age and risk of progression to ESRD under different genotypes and treatment conditions. RESULTS: A strong relationship between transcript type and renal outcome was observed, with the median age of ESRD onset being 22 years for truncating mutations and 39 years for non-truncating mutations. The response of affected patients to renin-angiotensin-aldosterone system (RAAS) blockers was genotype-associated. This therapy delayed the onset of ESRD by 16 years in patients with non-truncating mutations and 3 years in patients with truncating mutations. The efficacy of RAAS blockers functioned in a time-dependent manner, with a 7% reduction in the risk of progression to ESRD per each 6-month increase in treatment duration [hazard ratio 0.93 (95% confidence interval 0.89-0.96); P < 0.001]. CONCLUSIONS: Clinical features and response to RAAS blockers were observed to be strongly correlated with the genotypes of male XLAS patients. Genotyping of COL4A5 gene mutations is essential and is a useful tool to assess the prognosis of AS patients.
引用
- Di H, Zhang J, Gao E, et al. Dissecting the genotype-phenotype correlation of COL4A5 gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome. Nephrol Dial Transplant. 2022. PMID: 35020912. doi:10.1093/ndt/gfac002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。